Draft:Cerebral Cavernous Malformation

BioAxone BioSciences Expands Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors

Retrieved on: 
Monday, December 16, 2019
Biotechnology, Pharmaceutical, Genetics, Health, Benign neoplasms, Cavernous hemangioma, Medicine, Cavernous sinus, CCM, Clinical medicine, Health, Draft:Cerebral Cavernous Malformation, Central nervous system cavernous hemangioma, Biotechnology, Pharmaceutical, Genetics, Health, Benign neoplasms, Cavernous hemangioma, Medicine, Cavernous sinus, CCM, Clinical medicine, Health, Draft:Cerebral Cavernous Malformation, Central nervous system cavernous hemangioma

The notice refers to a critical patent application (US 15/988,736) covering the oral drug candidate in development, BA-1049.

Key Points: 
  • The notice refers to a critical patent application (US 15/988,736) covering the oral drug candidate in development, BA-1049.
  • Data from a recent clinical study indicates that BA-1049 has promise as a therapeutic agent for the treatment of cavernous angioma (CA), also called cerebral cavernous malformation (CCM).
  • CA is a serious genetic disease with no current treatment available other than surgical removal of the brain lesions.
  • We are very pleased with this expansion of our patent estate for BA-1049, said Lisa McKerracher, PhD, CEO, BioAxone BioSciences.

BioAxone BioSciences Announces Publication in Translational Stroke Research of Cavernous Angioma Disease Research Article

Retrieved on: 
Thursday, September 12, 2019
Biotechnology, Health, Genetics, Pharmaceutical, Benign neoplasms, Organ systems, Epidemiology, Medicine, Cavernous hemangioma, Angioma, Stroke, Brain damage, Central nervous system cavernous hemangioma, Draft:Cerebral Cavernous Malformation

CA is a rare genetic disease with no current treatment available other than surgical removal of the brain lesions.

Key Points: 
  • CA is a rare genetic disease with no current treatment available other than surgical removal of the brain lesions.
  • CA (also called cerebral cavernous malformation (CCM) is a serious genetic disease.
  • In angioma, endothelial cells form single or multiple cystic brain lesions that leak and may cause seizure, hemorrhagic stroke and neurological deficits.
  • Leveraging 20 years of pioneering research in axon regeneration and diseases involving Rho/ROCK signaling, BioAxones lead drug candidate is an orally-available ROCK2 inhibitor restoring endothelial cell barriers in cavernous angioma (CA) and stroke.